Daniel Kemp, PhD, DABT

Cell Therapy Development Leader

Dan is focused on the delivery of cell therapies from preclinical development to commercial products. He joined Precision from Quintiles, where he served as a Senior Director in the Strategic Drug Development group, focused on the submission of small molecules, biologics, and regenerative medicine products to the FDA or European Medicines Agency. Prior to Quintiles, Dan worked in several pharma and biotech companies, both large and small, including GlaxoSmithKline and Targacept. He is an American Board of Toxicology (ABT) Diplomate, on the Board of Directors for ABT, and an Adjunct Professor at UNC Chapel Hill. Dan received his PhD in Toxicology from UNC and his BS in Biochemistry from Michigan State University. When not at Precision, Dan can be found convincing his wife he needs to run another Spartan race, chauffeuring his kids for their endless activities, or riding his Harley.